Loading clinical trials...
Loading clinical trials...
Demonstrate ability of SEP-363856 to be superior to placebo as an adjunctive therapy to ADT in change from baseline in depressive symptoms (MADRS \& CGI-S) in MDD patients who had an inadequate respon...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
NCT07592689 · Major Depressive Disorder
NCT07539805 · Major Depressive Disorder (MDD), Probiotic Intervention
NCT07645157 · Major Depressive Disorder (MDD), Probiotic Intervention
NCT07642882 · Fibromyalgia, Depression - Major Depressive Disorder, and more
NCT07621237 · Major Depressive Episode (MDE), Major Depressive Disorder (MDD), and more
University of Alabama at Birmingham
Birmingham, Alabama
Scottsdale Clinical Research
Scottsdale, Arizona
DelSol Research
Tucson, Arizona
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions